Nuvectis Carries No Liability For Up To About $1.4 Billion In Haisco Payments After Early Accounting Switch

The drug developer says none of the contingent payments to its China-based licensor were considered probable as of September 30, 2026.

Share
Nuvectis Carries No Liability For Up To About $1.4 Billion In Haisco Payments After Early Accounting Switch

Nuvectis Pharma, a clinical-stage biotech developing treatments for complement-related conditions and cancer, records no liability for up to approximately $1.4 billion in contingent payments to Haisco Pharmaceutical Group, according to its quarterly report filed Wednesday. Since January 1, 2026, after an early-adopted accounting update, those payments no longer fall under derivative accounting.

How the Haisco payments are booked

Nuvectis licensed two drug candidates, NXP100 (ciprocopan) and NXP200, from Haisco under an agreement signed June 22, 2026. It paid a $20.0 million upfront fee in July and booked it as research and development expense, because the acquired assets had not won regulatory approval and had no alternative use.

The company classes milestone, royalty, sublicense and change-of-control payments as contingent consideration. After adopting ASU 2025-07, the company says they fall under contingency accounting, so they are recognized only when probable and reasonably estimable. As of September 30, 2026, none met that bar, and the company said the early adoption did not have a material impact on its statements.

The prior quarter's filing carried no such discussion of the standard.

How future milestones will hit earnings

Milestone and change-of-control payments tied to programs without approval will be expensed as research and development. Once a product is approved, payments owed will be booked as intangible assets and written off over that product's useful life. Royalty and sublicense payments will be recorded as cost of sales.

Net sales will also earn Haisco tiered royalties, ranging from the high-single digits to the mid-teens. A change-of-control payment of a low double-digit percentage of the licensed rights' appraised fair market value applies if Nuvectis completes or agrees to such a transaction within eighteen months of the June 22, 2026 signing.

Cash, losses and the pipeline

Nuvectis ended the quarter with $140.7 million in cash, up from $31.6 million at the end of 2025. Its net loss for the third quarter was $30.1 million, against $7.5 million a year earlier, and the quarter includes the $20.0 million Haisco payment and $1.8 million in NXP900 milestones. The company's earnings release says $39.5 million of at-the-market share sales, of which $37.0 million went to a single healthcare-dedicated fund, supplemented a $115.0 million July follow-on offering. Management says the cash funds operations into the second half of 2029.

Ciprocopan was approved in China in July for PNH, a rare blood disorder, in patients not previously treated with complement inhibitors. The company has 19 full-time employees as of October 30, 2026, up from 16 at July 31. Its market value was $631 million in Wednesday morning trading.

The company said an FDA update on the U.S. path for ciprocopan in PNH is expected before year-end, along with U.S. IND submissions for NXP100 and NXP200.

Sources

More on Nuvectis Pharma

All Nuvectis Pharma (NVCT) coverage →